1. Home
  2. PHR vs LTGO Comparison

PHR vs LTGO Comparison

Compare PHR & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phreesia Inc.

PHR

Phreesia Inc.

N/A

Current Price

$12.58

Market Cap

788.3M

ML Signal

N/A

Logo Latigo Biotherapeutics Inc. Common Stock

LTGO

Latigo Biotherapeutics Inc. Common Stock

N/A

Current Price

$13.68

Market Cap

924.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PHR
LTGO
Founded
2005
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
788.3M
924.9M
IPO Year
2019
2026

Fundamental Metrics

Financial Performance
Metric
PHR
LTGO
Price
$12.58
$13.68
Analyst Decision
Buy
Strong Buy
Analyst Count
18
4
Target Price
$13.93
★ $52.25
AVG Volume (30 Days)
★ 633.2K
214.8K
Earning Date
12-07-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 103.92
N/A
EPS
★ 0.08
N/A
Revenue
★ $480,591,000.00
N/A
Revenue This Year
$7.32
N/A
Revenue Next Year
$3.73
N/A
P/E Ratio
$155.56
★ N/A
Revenue Growth
★ 14.48
N/A
52 Week Low
$7.77
$13.50
52 Week High
$23.31
$25.93

Technical Indicators

Market Signals
Indicator
PHR
LTGO
Relative Strength Index (RSI) 69.00 36.77
Support Level $11.38 $13.50
Resistance Level $12.70 $17.67
Average True Range (ATR) 0.47 1.39
MACD 0.09 0.07
Stochastic Oscillator 89.79 4.25

Price Performance

Historical Comparison
PHR
LTGO

About PHR Phreesia Inc.

Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: